Inhibrx Biosciences
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 3 weeks.
- Its last 3 Sell calls were followed by a 12% average decline over the next quarter.
- Recent price momentum is -22.0% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 23.0% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2849 U.S. stocks StockVane covers.
Last computed: 2026-11-21 14:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability F
How much profit the business keeps from each dollar of sales and capital.
| Operating margin | -10,386.5% | Better than 1% |
| Net margin | -10,773.5% | Better than 1% |
| Return on equity | -197.8% | Better than 3% |
| Return on invested capital | -106.5% | Better than 2% |
Momentum D+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -33.4% | Better than 15% |
| 6-month return | -31.9% | Better than 17% |
| 12-month return (ex latest month) | 15.7% | Better than 54% |
| Distance below 52-week high | 55.6% | Better than 14% |
Financial Health D+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 3.9x | Better than 81% |
| Debt to assets | 73.1% | Better than 5% |
| Interest coverage | -10.5x | Better than 13% |
Analyst View A+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 286.6% | Better than 97% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 74.33
- Open
- 72.72
- Day range
- 68.78 - 74.60
- Avg price
- 71.09
- Volume
- 252.13K
- Turnover
- 17.92M
- Turnover ratei
- 3.12%
- Volume ratioi
- 0.82
- Amplitudei
- 7.83%
- 52-week rangei
- 57.30 - 155.29
Valuation
- P/Ei
- -7.63
- P/E (TTM)i
- -7.61
- P/Bi
- -11.86
- EPSi
- -9.04
- Book value / shi
- -5.82
- Net profit
- -133.51M
- Net assets
- -85.88M
Share structure
- Market cap
- 1.02B
- Float capi
- 557.55M
- Shares out
- 14.77M
- Float sharesi
- 8.08M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2024-05-28
55.6% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+5.60M net over the window
Short interest
- Shares short
- 3.39M
- % of floati
- 23.03%
- Days to coveri
- 10.00
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Inhibrx Biosciences (INBX)?
Inhibrx Biosciences last traded at 68.97. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Inhibrx Biosciences's market cap?
About 1.02B.
What is the P/E ratio of Inhibrx Biosciences?
The trailing twelve-month P/E is -7.61. The Valuation tab shows it against the stock's own five-year range.
Does Inhibrx Biosciences pay a dividend?
Inhibrx Biosciences does not currently pay a regular dividend.
Is Inhibrx Biosciences a buy according to analysts?
The consensus of 3 analysts is a Buy rating, with an average 12-month price target of 266.67, which implies 286.6% upside from the current price. This is not investment advice.
What is Inhibrx Biosciences's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Inhibrx Biosciences a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Inhibrx Biosciences discussion 0 comments